Minocycline mitigates tau pathology via modulating the TLR-4/NF- кβ signalling pathway in the hippocampus of neuroinflammation rat model
CONCLUSION: This study suggests that minocycline suppresses the neuroinflammation signalling pathway and decreased phosphorylated tau protein formation induced by LPS in a dose-dependent manner. Minocycline can be used as a preventative and therapeutic drug for neuroinflammatory diseases such as AD.PMID:38122814 | DOI:10.1080/01616412.2023.2296754 (Source: Neurological Research)
Source: Neurological Research - December 20, 2023 Category: Neurology Authors: Entesar Yaseen Abdo Qaid Zuraidah Abdullah Rahimah Zakaria Idris Long Source Type: research
Mobilization of the innate immune response by a specific immunostimulant β-glucan confers resistance to chronic stress-induced depression-like behavior by preventing neuroinflammatory responses
Int Immunopharmacol. 2023 Dec 19;127:111405. doi: 10.1016/j.intimp.2023.111405. Online ahead of print.ABSTRACTPre-stimulation of the innate immune response is an effective strategy to prevent depression-like phenotypes in animals. However, the use of conventional immunostimulants may cause adverse effects. Therefore, the search for agents that stimulate the innate immune response but do not induce a pro-inflammatory response could be a new research direction for the prevention of depression. β-glucan is a polysaccharide from Saccharomyces cerevisiae with unique immunomodulatory activity in microglia without eliciting a pr...
Source: International Immunopharmacology - December 20, 2023 Category: Allergy & Immunology Authors: Jie Ren Yi Zhang Hainan Pan Ruiting Shi Haojie Zhu Rongrong Yang Lin Zhang Bingran Chen Tao Zhu Xu Lu Chao Huang Source Type: research
Minocycline mitigates tau pathology via modulating the TLR-4/NF- кβ signalling pathway in the hippocampus of neuroinflammation rat model
CONCLUSION: This study suggests that minocycline suppresses the neuroinflammation signalling pathway and decreased phosphorylated tau protein formation induced by LPS in a dose-dependent manner. Minocycline can be used as a preventative and therapeutic drug for neuroinflammatory diseases such as AD.PMID:38122814 | DOI:10.1080/01616412.2023.2296754 (Source: Neurological Research)
Source: Neurological Research - December 20, 2023 Category: Neurology Authors: Entesar Yaseen Abdo Qaid Zuraidah Abdullah Rahimah Zakaria Idris Long Source Type: research
Mobilization of the innate immune response by a specific immunostimulant β-glucan confers resistance to chronic stress-induced depression-like behavior by preventing neuroinflammatory responses
Int Immunopharmacol. 2023 Dec 19;127:111405. doi: 10.1016/j.intimp.2023.111405. Online ahead of print.ABSTRACTPre-stimulation of the innate immune response is an effective strategy to prevent depression-like phenotypes in animals. However, the use of conventional immunostimulants may cause adverse effects. Therefore, the search for agents that stimulate the innate immune response but do not induce a pro-inflammatory response could be a new research direction for the prevention of depression. β-glucan is a polysaccharide from Saccharomyces cerevisiae with unique immunomodulatory activity in microglia without eliciting a pr...
Source: International Immunopharmacology - December 20, 2023 Category: Allergy & Immunology Authors: Jie Ren Yi Zhang Hainan Pan Ruiting Shi Haojie Zhu Rongrong Yang Lin Zhang Bingran Chen Tao Zhu Xu Lu Chao Huang Source Type: research
Minocycline mitigates tau pathology via modulating the TLR-4/NF- кβ signalling pathway in the hippocampus of neuroinflammation rat model
CONCLUSION: This study suggests that minocycline suppresses the neuroinflammation signalling pathway and decreased phosphorylated tau protein formation induced by LPS in a dose-dependent manner. Minocycline can be used as a preventative and therapeutic drug for neuroinflammatory diseases such as AD.PMID:38122814 | DOI:10.1080/01616412.2023.2296754 (Source: Neurological Research)
Source: Neurological Research - December 20, 2023 Category: Neurology Authors: Entesar Yaseen Abdo Qaid Zuraidah Abdullah Rahimah Zakaria Idris Long Source Type: research
Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder
J Autism Dev Disord. 2023 Dec 15. doi: 10.1007/s10803-023-06132-1. Online ahead of print.ABSTRACTNeuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatm...
Source: Journal of Autism and Developmental Disorders - December 15, 2023 Category: Psychiatry Authors: Craig A Erickson Rebecca C Shaffer Meredith Will Lauren M Schmitt Paul Horn Kathy Hirst Ernest V Pedapati Nicole Ober Rameshwari V Tumuluru Benjamin L Handen David Q Beversdorf Source Type: research
Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder
J Autism Dev Disord. 2023 Dec 15. doi: 10.1007/s10803-023-06132-1. Online ahead of print.ABSTRACTNeuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatm...
Source: Journal of Autism and Developmental Disorders - December 15, 2023 Category: Psychiatry Authors: Craig A Erickson Rebecca C Shaffer Meredith Will Lauren M Schmitt Paul Horn Kathy Hirst Ernest V Pedapati Nicole Ober Rameshwari V Tumuluru Benjamin L Handen David Q Beversdorf Source Type: research
An update on combination therapies for multiple sclerosis: where are we now?
Expert Rev Neurother. 2023 Dec 6:1-15. doi: 10.1080/14737175.2023.2289572. Online ahead of print.ABSTRACTINTRODUCTION: In theory, combination of two agents, which are suboptimal when given individually, may result in a significant increase in therapeutic effect. Combination therapies have proven particularly effective against infections such as HIV, cancer, and also chronic autoimmune diseases such as rheumatoid arthritis.AREAS COVERED: The authors review the literature, searching for randomized placebo-controlled or comparative, double-blind or investigator-blinded clinical trials, not including open label clinical trials...
Source: Expert Review of Neurotherapeutics - December 7, 2023 Category: Neurology Authors: Per Soelberg Sorensen Melinda Magyari Finn Sellebjerg Source Type: research
Minocycline-induced Hyperpigmentation Confined to Lupus Miliaris Disseminatus Faciei
Acta Derm Venereol. 2023 Dec 7;103:adv18462. doi: 10.2340/actadv.v103.18462.NO ABSTRACTPMID:38059580 | DOI:10.2340/actadv.v103.18462 (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - December 7, 2023 Category: Dermatology Authors: Masakazu Kakurai Rie Honda Hanako Miyahara Shusaku Ito Source Type: research
